收费全文 | 27434篇 |
免费 | 2143篇 |
国内免费 | 585篇 |
耳鼻咽喉 | 202篇 |
儿科学 | 532篇 |
妇产科学 | 846篇 |
基础医学 | 3504篇 |
口腔科学 | 502篇 |
临床医学 | 3585篇 |
内科学 | 5245篇 |
皮肤病学 | 390篇 |
神经病学 | 2050篇 |
特种医学 | 639篇 |
外国民族医学 | 3篇 |
外科学 | 3505篇 |
综合类 | 1607篇 |
现状与发展 | 3篇 |
一般理论 | 44篇 |
预防医学 | 2018篇 |
眼科学 | 916篇 |
药学 | 2070篇 |
6篇 | |
中国医学 | 578篇 |
肿瘤学 | 1917篇 |
2024年 | 44篇 |
2023年 | 267篇 |
2022年 | 549篇 |
2021年 | 868篇 |
2020年 | 554篇 |
2019年 | 671篇 |
2018年 | 772篇 |
2017年 | 653篇 |
2016年 | 639篇 |
2015年 | 856篇 |
2014年 | 1081篇 |
2013年 | 1293篇 |
2012年 | 1896篇 |
2011年 | 2046篇 |
2010年 | 1191篇 |
2009年 | 983篇 |
2008年 | 1499篇 |
2007年 | 1599篇 |
2006年 | 1614篇 |
2005年 | 1589篇 |
2004年 | 1377篇 |
2003年 | 1196篇 |
2002年 | 1183篇 |
2001年 | 659篇 |
2000年 | 629篇 |
1999年 | 590篇 |
1998年 | 287篇 |
1997年 | 279篇 |
1996年 | 229篇 |
1995年 | 175篇 |
1994年 | 159篇 |
1993年 | 122篇 |
1992年 | 285篇 |
1991年 | 274篇 |
1990年 | 243篇 |
1989年 | 212篇 |
1988年 | 174篇 |
1987年 | 172篇 |
1986年 | 163篇 |
1985年 | 127篇 |
1984年 | 105篇 |
1983年 | 83篇 |
1982年 | 88篇 |
1981年 | 77篇 |
1980年 | 73篇 |
1979年 | 78篇 |
1978年 | 67篇 |
1977年 | 45篇 |
1975年 | 45篇 |
1974年 | 35篇 |
OBJECTIVE:
Aneurysmal subarachnoid hemorrhage puts patients at high risk for the development of pituitary insufficiency. We evaluated the incidence of pituitary dysfunction in these patients and its correlation with clinical outcome.METHODS:
Pituitary function was tested in 66 consecutive patients in the first 15 days after aneurysmal subarachnoid hemorrhage. The following were measured in all patients: thyroid-stimulating hormone, free thyroxine, triiodothyronine, luteinizing hormone, follicle-stimulating hormone, total testosterone (in males), estradiol (in females), prolactin, serum cortisol, plasma adrenocorticotropic hormone, growth hormone and insulin growth factor.RESULTS:
The endocrine assessment was made at a mean of 7.4 days (standard deviation ±6.6) after subarachnoid hemorrhage. Forty-four (66.7%) female and 22 (33.3%) male patients were evaluated. Thirty-nine patients (59.1%) had some type of pituitary dysfunction. Follicle-stimulating hormone/luteinizing hormone deficiency was the most frequent disorder (34.8%), followed by growth hormone/insulin growth factor (28.7%), adrenocorticotropic hormone (18.1%) and thyroid-stimulating hormone (9%). Seventeen (25.7%) patients showed deficiencies in more than one axis. A greater incidence of hormone deficiency was observed in patients with a Glasgow Coma Scale score ≤13 (t test, p = 0.008), Hunt-Hess grade ≥4 (t test, p<0.001), or Fisher grade 4 (t test, p = 0.039). Hormone deficiency was not significantly associated (p>0.05) with increased hospitalization or clinical outcome.CONCLUSION:
Pituitary dysfunction was identified in a substantial portion of patients with previous aneurysmal subarachnoid hemorrhage, but no association was found between this dysfunction and poor clinical outcome. 相似文献Interstitial lung disease (ILD) represents a significant cause of morbidity and mortality in systemic sclerosis (SSc). The purpose of this study was to examine recirculating lymphocytes from SSc patients for potential biomarkers of interstitial lung disease (ILD). Peripheral blood mononuclear cells (PBMCs) were isolated from patients with SSc and healthy controls enrolled in the Vanderbilt University Myositis and Scleroderma Treatment Initiative Center cohort between 9/2017–6/2019. Clinical phenotyping was performed by chart abstraction. Immunophenotyping was performed using both mass cytometry and fluorescence cytometry combined with t-distributed stochastic neighbor embedding analysis and traditional biaxial gating. This study included 34 patients with SSc-ILD, 14 patients without SSc-ILD, and 25 healthy controls. CD21lo/neg cells are significantly increased in SSc-ILD but not in SSc without ILD (15.4 ± 13.3% vs. 5.8 ± 0.9%, p = 0.002) or healthy controls (5.0 ± 0.5%, p < 0.0001). While CD21lo/neg B cells can be identified from a single biaxial gate, tSNE analysis reveals that the biaxial gate is comprised of multiple distinct subsets, all of which are increased in SSc-ILD. CD21lo/neg cells in both healthy controls and SSc-ILD are predominantly tBET positive and do not have intracellular CD21. Immunohistochemistry staining demonstrated that CD21lo/neg B cells diffusely infiltrate the lung parenchyma of an SSc-ILD patient. Additional work is needed to validate this biomarker in larger cohorts and longitudinal studies and to understand the role of these cells in SSc-ILD.
相似文献